$0.58
+0.01 (+2.16%)
Open$0.59
Previous Close$0.57
Day High$0.62
Day Low$0.56
52W High$9.60
52W Low$0.50
Volume—
Avg Volume56.1K
Market Cap2.57M
P/E Ratio—
EPS$-5.61
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+781.6% upside
Current
$0.58
$0.58
Target
$5.14
$5.14
$3.59
$5.14 avg
$6.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 484.7K | 468.9K | 455.7K |
| Net Income | -93,000 | -114,838 | -98,507 |
| Profit Margin | -19.2% | -24.5% | -21.6% |
| EBITDA | -101,936 | -104,145 | -94,610 |
| Free Cash Flow | -84,967 | -104,034 | -103,597 |
| Rev Growth | +6.2% | -0.5% | +16.3% |
| Debt/Equity | 0.77 | 0.85 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |